EUVIMEDEUVIMED entdecken
Crossref

Early Anti-Müllerian Hormone Levels in Adverse Pregnancy Outcomes in Women without Polycystic Ovary Syndrome

Ferhan Zengin Sadef, Berke Yesiltas, Burcu Dincgez, Gulten Ozgen, Tayfur Cift

Zeitschrift für Geburtshilfe und Neonatologie · 01.04.2026 · 230 (02) · 103-108

DOI: 10.1055/a-2743-4575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Geburtshilfe und Neonatologie, erschienen am 01.04.2026. Verfasst von Ferhan Zengin Sadef und 4 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynecology, Yozgat State Hospital, Yozgat, Turkey. Hauptthemen laut MEDLINE: Anti-Mullerian Hormone, Pregnancy Outcome, Pregnancy Trimester, First, Pregnancy Complications. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-Müllerian hormone (AMH) is commonly used in artificial reproductive treatments. Unfortunately, there is only limited data about AMH in adverse pregnancy outcomes. Here, we searched the role of first-trimester AMH to predict adverse pregnancy outcomes in women without polycystic ovary syndrome (PCOS). A total of 240 pregnant women were enrolled in this prospective study. The inclusion criteria were being in the first trimester of pregnancy, having AMH levels measured, not having PCOS, and having had regular antenatal visits. Adverse outcomes were preeclampsia, gestational hypertension, gestational diabetes, preterm birth, pregnancy loss, and stillbirth. Demographic features, obstetric outcomes, and AMH levels were recorded and compared for each adverse outcome. AMH levels were lower in preeclampsia, gestational hypertension, gestational diabetes, and pregnancy loss compared to the control group. In ROC analysis, a cut-off value of 2.14 ng/mL for predicting preeclampsia yielded a sensitivity of 84.2% and specificity of 55.5% (p=0.027, AUC=0.658). For gestational hypertension, a threshold of 2.65 ng/mL resulted in a sensitivity of 94.4% and specificity of 41.2% (p=0.004, AUC=0.662). In predicting gestational diabetes, a cut-off of 1.98 ng/mL achieved a sensitivity of 83.3% and specificity of 59.7% (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Mullerian HormonePregnancy OutcomePregnancy Trimester, FirstPregnancy ComplicationsHumansFemalePregnancyAdultBiomarkersSensitivity and SpecificityPolycystic Ovary SyndromeProspective StudiesDiabetes, GestationalYoung AdultPre-EclampsiaReproducibility of ResultsRisk Factors

Substanzen

Anti-Mullerian HormoneBiomarkers

Autor:innen und Institutionen

  • Obstetrics and Gynecology, Yozgat State Hospital, Yozgat, Turkey.
  • Obstetrics and Gynecology, Afyon Suhut State Hospital, Afyon, Turkey.
  • Department of Obstetrics and Gynecology, Bursa Yuksek Ihtisas Research and Training Hospital, University of Health Sciences, Bursa, Turkey.
  • Department of Obstetrics and Gynecology, Nev Esentepe Hospital, Bursa, Turkey.

Zitieren

APA

Zengin Sadef, F., Yesiltas, B., Dincgez, B., Ozgen, G., & Cift, T. (2026). Early Anti-Müllerian Hormone Levels in Adverse Pregnancy Outcomes in Women without Polycystic Ovary Syndrome. Zeitschrift für Geburtshilfe und Neonatologie, 230(02), 103-108. https://doi.org/10.1055/a-2743-4575

Vancouver

Zengin Sadef F, Yesiltas B, Dincgez B, Ozgen G, Cift T. Early Anti-Müllerian Hormone Levels in Adverse Pregnancy Outcomes in Women without Polycystic Ovary Syndrome. Zeitschrift für Geburtshilfe und Neonatologie. 2026;230(02):103-108. doi:10.1055/a-2743-4575

BibTeX
@article{ZenginSadef2026,
  author = {Zengin Sadef, Ferhan and Yesiltas, Berke and Dincgez, Burcu and Ozgen, Gulten and Cift, Tayfur},
  title = {Early Anti-Müllerian Hormone Levels in Adverse Pregnancy Outcomes in Women without Polycystic Ovary Syndrome},
  journal = {Zeitschrift für Geburtshilfe und Neonatologie},
  year = {2026},
  volume = {230},
  number = {02},
  pages = {103--108},
  doi = {10.1055/a-2743-4575}
}
Kostenlos starten →